AGO2/Argonaute-2 Protein, Mouse (sf9, His)
Based on 1 publication(s) in Google Scholar
The AGO2/Argonaute-2 protein is essential for RNA-mediated gene silencing via the RNA-induced silencing complex (RISC). "Minimal RISC" involves AGO2 binding to a guide RNA, such as microRNA (miRNA) or short interfering RNA (siRNA), which guides RISC for silencing with complementary mRNA. AGO2/Argonaute-2 Protein, Mouse (sf9, His) is the recombinant mouse-derived AGO2/Argonaute-2 protein, expressed by Sf9 insect cells , with N-His labeled tag.
- Species: Mouse
- Source: Sf9 insect cells
-
Storage:Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.
Biological Activity
Description
The AGO2/Argonaute-2 protein is essential for RNA-mediated gene silencing via the RNA-induced silencing complex (RISC). "Minimal RISC" involves AGO2 binding to a guide RNA, such as microRNA (miRNA) or short interfering RNA (siRNA), which guides RISC for silencing with complementary mRNA. AGO2/Argonaute-2 Protein, Mouse (sf9, His) is the recombinant mouse-derived AGO2/Argonaute-2 protein, expressed by Sf9 insect cells , with N-His labeled tag.
Background
The AGO2/Argonaute-2 protein is crucial for RNA-mediated gene silencing facilitated by the RNA-induced silencing complex (RISC). The 'minimal RISC' comprises AGO2 bound to a short guide RNA, such as a microRNA (miRNA) or short interfering RNA (siRNA). These guide RNAs guide RISC to complementary mRNAs, initiating RISC-mediated gene silencing. The mechanism of gene silencing depends on the complementarity between the miRNA or siRNA and its target. Perfect complementarity leads to mRNA cleavage by AGO2, while partial complementarity results in translational inhibition, independent of endonuclease activity. AGO2 may inhibit translation initiation by binding to the 7-methylguanosine cap, preventing eIF4-E recruitment. It can also interact with EIF6, hindering the association of the 60S ribosomal subunit with the 40S subunit, leading to translational inhibition and mRNA accumulation in processing bodies. RISC-mediated translational repression is observed even for miRNAs with perfect 3'-UTR matches. Additionally, AGO2 plays a role in up-regulating translation under specific growth conditions, binding to the AU element in the 3'-UTR of TNF mRNA to enhance translation during serum starvation. Beyond its role in RNA silencing, AGO2 is essential for transcriptional gene silencing (TGS) where antigene RNAs or agRNAs direct the repression of complementary promoter regions. AGO2 regulates lymphoid and erythroid development and function independently of its endonuclease activity.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
ACS Appl Mater Interfaces
Targeted Delivery of AGO-2 to Myocardial Mitochondria via Functionalized Nanoparticles Attenuates Oxidative Stress in Diabetic Cardiomyopathy. [Abstract]2025 Dec 10;17(49):66298-66312. PMID: 41288605
Technical Parameters
-
Species Mouse
-
Source Sf9 insect cells
-
Tag N-His
-
Accession
Q8CJG0 (M1-A860)
-
Molecular Construction
-
N-term
-
His
-
AGO2 (M1-A860)
Accession # Q8CJG0 -
C-term
-
-
Protein Length
Full Length
-
Synonyms
AGO2; HAGO2; Prev. EIF2C2; Eukaryotic Translation Initiation Factor 2C 2; Prev. CASC7; Long Intergenic Non-Protein Coding RNA 980; LINC00980; Argonaute 2, RISC Catalytic Component; Q10; Argonaute 2; Cancer Susceptibility Candidate 7 (Non-Protein Coding);
-
AA Sequence
MYSGAGPVLASPAPTTSPIPGYAFKPPPRPDFGTTGRTIKLQANFFEMDIPKIDIYHYELDIKPEKCPRRVNREIVEHMVQHFKTQIFGDRKPVFDGRKNLYTAMPLPIGRDKVELEVTLPGEGKDRIFKVSIKWVSCVSLQALHDALSGRLPSVPFETIQALDVVMRHLPSMRYTPVGRSFFTASEGCSNPLGGGREVWFGFHQSVRPSLWKMMLNIDVSATAFYKAQPVIEFVCEVLDFKSIEEQQKPLTDSQRVKFTKEIKGLKVEITHCGQMKRKYRVCNVTRRPASHQTFPLQQESGQTVECTVAQYFKDRHKLVLRYPHLPCLQVGQEQKHTYLPLEVCNIVAGQRCIKKLTDNQTSTMIRATARSAPDRQEEISKLMRSASFNTDPYVREFGIMVKDEMTDVTGRVLQPPSILYGGRNKAIATPVQGVWDMRNKQFHTGIEIKVWAIACFAPQRQCTEVHLKSFTEQLRKISRDAGMPIQGQPCFCKYAQGADSVEPMFRHLKNTYAGLQLVVVILPGKTPVYAEVKRVGDTVLGMATQCVQMKNVQRTTPQTLSNLCLKINVKLGGVNNILLPQGRPPVFQQPVIFLGADVTHPPAGDGKKPSIAAVVGSMDAHPNRYCATVRVQQHRQEIIQDLAAMVRELLIQFYKSTRFKPTRIIFYRDGVSEGQFQQVLHHELLAIREACIKLEKDYQPGITFIVVQKRHHTRLFCTDKNERVGKSGNIPAGTTVDTKITHPTEFDFYLCSHAGIQGTSRPSHYHVLWDDNRFSSDELQILTYQLCHTYVRCTRSVSIPAPAYYAHLVAFRARYHLVDKEHDSAEGSHTSGQSNGRDHQALAKAVQVHQDTLRTMYFA
-
Predicted Molecular Mass
99 kDa
-
Molecular Weight
Approximately 105 kDa, based on SDS-PAGE under reducing conditions.
-
Purity
≥ 85%, as determined by reducing SDS-PAGE.
Product Properties
Lyophilized powder.
<1 EU/μg, determined by LAL method.
It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH2O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).
Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.
Room temperature in continental US; may vary elsewhere.
Documentation
-
Data Sheet (241 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)